Serum immunoglobulin levels in male schizophrenic patients before and after olanzapine therapy

Abstract

Objective: To evaluate the effect of olanzapine therapy on serum immunoglobulinlevels (IgA, IgG, IgM) in male schizophrenic patients after 2 months of treatment byolanzapine at a daily dose of 20 mg.Patients and Methods: Twenty-eight patients with schizophrenia were included inthis study, assessment of each case was done by a psychiatric, also included a 30healthy subjects as a control group. Serum immunoglobulin concentrations weredetermined for both patients and controls by Mancini Radial Immuno-diffusionmethod using immunoglobulin kits. For the patients group and after 2 months therapywith olanzapine at a fixed daily dose of 20 mg, serum immunoglobulins weredetermined again using the same method for the assay.Results: No significant difference was found between serum levels ofimmunoglobulin (IgA, IgG, IgM) in schizophrenic patients before therapy incomparison to controls. Also insignificant difference was found between serumimmunoglobulin levels (IgA, IgG, IgM) in schizophrenic patients after 2 months ofolanzapine therapy and the controls. By comparing serum immunoglobulin levels inpatients with schizophrenia before and 2 months after starting olanzapine therapy, nostatistically significant difference was found.Conclusion: Olanzapine as atypical antipsychotic may not have an influence on thehumoral immune response as reflected by the immunoglobulin levels (IgA, IgG, IgM)